To diagnose or not to diagnose? Timing is the question: balancing early diagnosis of multiple sclerosis with misdiagnosis

Click to increase image sizeClick to decrease image size

Declaration of interest

C Dixon has been a consultant for Sanofi Genzyme. D Robertson has been a consultant for Biogen, EMD Serono, Genentech, Genzyme, Novartis, and Teva; has received honoraria or speaker’s fees from Acorda, Biogen, EMD Serono, Genentech, Genzyme, Mallinckrodt, Novaris, and Teva Pharmaceuticals; and has received research grant support from Actelion, Biogen, EMD Serono, Genetech, Genzyme, Mallinckrodt, MedImmune, Novartis, Parexel, Sun Pharma, and TG Therapeutics. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. One peer reviewer was the lead author of the paper which is the subject of the editorial but have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.